We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

Buy low, sell high” is a common investing mantra. It’s easy to understand, but often hard to execute because emotion gets in ...

Health-care companies rose as investors bet on anti-obesity products. Omada Health shares jumped after the maker of digital products that help track diet and other diabetes factors made its ...

These five Dow Jones industrial companies have paid dividends to shareholders for at least 100 years, perfect ideas for ...

Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.

Diabetes care startup Omada Health went public Friday 14 years after its founding. Here's what its major investors' stakes ...

Happy Friday to Barchart readers, everywhere. I don’t know what the weather is like where you live, but here in Halifax, on ...

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

During the first quarter, the Harbor Health Care ETF returned 2.18% (NAV), outperforming the Russell 3000® Growth Health Care ...